Adimmune Corporation AI Stock Analysis
Adimmune Corporation (4142) AI Stock Analysis
Adimmune Corporation
(TWSE:4142)
The overall score is at the minimum of 37, reflecting a convergence of severe risks across all evaluated components. The most significant factor is the company's critical financial state, characterized by persistent losses and a dangerous cash burn rate that threatens sustainability. This is compounded by a bearish technical outlook, with the stock in a clear downtrend and showing no signs of reversal. The negative P/E ratio further confirms the lack of earnings power. The company's financial trajectory is a significant concern with no mitigating factors present.
Adimmune Corporation (4142) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 7.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 994.87K
- Price to Earnings (P/E)
- -48.7
- Beta (1Y)
- 0.47
- Revenue Growth
- 34.06%
- EPS Growth
- ―
- Country
- TW
- Employees
- 564
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Adimmune Corporation Business Overview & Revenue Model
Company Description
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influen...
Adimmune Corporation Financial Statement Overview
Summary
Financial performance is critically weak. The Income Statement (Score 18) shows persistent operating losses and deteriorating margins. The Cash Flow Statement (Score 10) reveals a severe cash burn with deeply negative free cash flow. The Balance Sheet (Score 55) is the only relative bright spot, but the trend of increasing leverage and negative returns on equity is concerning. The overall financial health is under severe strain.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.40B | 1.56B | 1.79B | 2.25B | 1.64B |
| Gross Profit | 306.32M | 288.49M | 448.06M | 410.94M | 891.08M | 464.14M |
| EBITDA | -40.87M | -144.69M | -84.30M | -512.43M | 438.12M | 254.89M |
| Net Income | -233.50M | -239.89M | -242.75M | -639.89M | 290.98M | 43.07M |
Balance Sheet | ||||||
| Total Assets | 8.11B | 8.19B | 8.48B | 9.48B | 9.15B | 8.01B |
| Cash, Cash Equivalents and Short-Term Investments | 1.82B | 2.24B | 2.47B | 2.49B | 2.97B | 2.89B |
| Total Debt | 3.03B | 2.83B | 2.60B | 3.14B | 2.26B | 1.32B |
| Total Liabilities | 3.41B | 3.14B | 2.92B | 3.71B | 2.60B | 1.58B |
| Stockholders Equity | 4.62B | 4.94B | 5.23B | 5.47B | 6.12B | 6.15B |
Cash Flow | ||||||
| Free Cash Flow | -264.41M | -242.18M | 513.26M | -1.11B | -711.59M | -1.33B |
| Operating Cash Flow | -64.25M | -5.45M | 668.48M | -892.35M | -291.96M | -480.52M |
| Investing Cash Flow | -171.79M | -198.98M | -310.90M | -366.56M | -322.07M | -728.84M |
| Financing Cash Flow | 147.63M | 56.19M | -478.80M | 859.30M | 823.19M | -222.89M |
Adimmune Corporation Peers Comparison
Overall Rating
TW:416954Neutral
TW:417448Neutral
TW:412844Neutral
TW:654143Neutral- TW:414237Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4169 | 54Neutral | TWD 7.93B | -291.25 | ― | 0.27% | ― | ― |
| TW:4174 | 48Neutral | TWD 7.23B | -2.37 | ― | ― | -2.20% | 29.08% |
| TW:4128 | 44Neutral | TWD 7.85B | 24.61 | ― | ― | 4.85% | ― |
| TW:6541 | 43Neutral | TWD 7.47B | -5.03 | -26.61% | ― | 207.37% | 4.17% |
| TW:4142 | 37Underperform | TWD 7.22B | -48.68 | ― | ― | 34.06% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4142 | Adimmune Corporation | 16.60 | -4.95 | -22.97% | |
| TW:6541 | Tanvex Biopharma | 28.15 | -27.35 | -49.28% | |
| TW:4128 | Microbio Co., Ltd. | 13.45 | -6.85 | -33.74% | |
| TW:4169 | TCM Biotech International Corp. | 116.50 | -63.27 | -35.20% | |
| TW:4174 | OBI Pharma, Inc. | 60.50 | 10.70 | 21.49% | |
| TW:7876 | Obigen Pharma, Inc. | 66.20 | 29.51 | 80.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026